Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Calcineurin Inhibitors/therapeutic use , Cyclophosphamide/therapeutic use , Cystitis/drug therapy , Cystitis/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Polyomavirus/pathogenicity , Transplantation Conditioning/adverse effects , Antineoplastic Agents, Alkylating/pharmacology , Calcineurin Inhibitors/adverse effects , Calcineurin Inhibitors/pharmacology , Cyclophosphamide/pharmacology , Cystitis/pathology , Female , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Retrospective Studies , Transplantation Conditioning/methodsSubject(s)
Hodgkin Disease/therapy , Neoplasm Recurrence, Local/therapy , Stem Cell Transplantation , Adolescent , Adult , Disease Progression , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Retrospective Studies , Time Factors , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , Young AdultSubject(s)
Cytomegalovirus Infections , Hematopoietic Stem Cell Transplantation/adverse effects , Transplantation, Haploidentical/adverse effects , Adolescent , Adult , Aged , Cohort Studies , Cyclophosphamide/therapeutic use , Female , Hematologic Neoplasms/complications , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/mortality , Humans , Lymphocyte Depletion , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
BACKGROUND AND OBJECTIVES: Several transplantation outcomes have been shown to be associated with the infused bone marrow cell dose/kg of the recipient's body weight. The donor bone marrow density is directly related to the infused cell dose. The aim of the present study was to identify donor-related variables that are associated with high donor bone marrow density. MATERIALS AND METHODS: We retrospectively analysed the predictive factors of high marrow density in 65 consecutive HLA-haploidentical bone marrow donors harvested at our centre between 2009 and 2013. RESULTS: Body mass index (BMI) and peripheral white blood cell (WBC) count were directly associated with bone marrow density (regression coefficient ß = 5·33 and ß = 2·93, respectively; P < 0·01). The likelihood of obtaining a collection with a high density was first predicted using BMI (BMI ≥30, mean density = 25·8 TNC/ml × 10(6) ). Second, donors with a BMI <30 were split into two groups according to peripheral WBC count (WBC <8 × 10(3) /mm(3) : mean density = 18·4 TNC/ml × 10(6) ; WBC ≥8 × 10(3) /mm(3) : mean density = 23·1 TNC/ml × 10(6) ). We also observed that the density of the first collected bag directly correlated with the overall density (R(2) = 0·69, P < 0·01). CONCLUSION: The donor-related features BMI and WBC count affect the cell quantity obtainable with the harvest and should be taken into account when choosing the donor.
